State-of-the-art strategies for targeting the DNA damage response in cancer
2018 · Nature Reviews Clinical Oncology · 1,165 citations
https://doi.org/10.1038/s41571-018-0114-z
P
Patrick G. Pilié
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
366
Papers
3.7K
Citations
21
h-index
32
i10-index
Patrick G. Pilié is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: interferon and immune responses & PARP inhibition in cancer therapy & Prostate Cancer Treatment and Research. The author has an h-index of 21, co-authored 312 publications.
ORCID: 0000-0001-8759-0020Papers by this author
worksPARP Inhibitors: Extending Benefit Beyond <i>BRCA</i>-Mutant Cancers
2019 · Clinical Cancer Research · 324 citations
https://doi.org/10.1158/1078-0432.ccr-18-0968
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
2023 · JAMA Oncology · 171 citations
https://doi.org/10.1001/jamaoncol.2023.0161
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
2020 · Nature Communications · 169 citations
https://doi.org/10.1038/s41467-020-15959-6
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
2023 · Nature Genetics · 131 citations
https://doi.org/10.1038/s41588-023-01534-4
Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives.
2025 · Journal of Clinical Oncology · 3 citations
https://doi.org/10.1200/jco.2025.43.5_suppl.140
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat